A marked and rapid reduction in PCV13 serotype, the most common antibiotic-nonsusceptible S pneumoniae, carriage was observed in both ethnic populations included in this study.
Patients with voriconazole-resistant invasive aspergillosis have a higher mortality rate compared with patients with voriconazole-susceptible infection.
A meta-analysis of case-control studies supports the use of the 13-valent pneumococcal conjugate vaccine in children as it protects against serotype 3.
Repeated exposure to the influenza virus affects antibody quantity and quality, and strains selected for seasonal vaccines may not provide coverage sufficient for individuals frequently infected and/or vaccinated.
The use of fluoroquinolones in stable patients with community-acquired pneumonia can be reduced with stewardship programs that share antibiotic use data and provide guidance for step-down therapy.
